By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Arrowhead Research Corporation 

1118 East Green Street

Pasadena  California  91106  U.S.A.
Phone: 626-792-5549 Fax: 626-792-5554


Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary drug delivery technologies to develop targeted drugs based on the RNA interference mechanism that efficiently silence disease-causing genes. Arrowhead technologies also enable partners to create peptide-drug conjugates that specifically home to cell types of interest while sparing off-target tissues. Arrowhead’s pipeline includes clinical programs in chronic hepatitis B virus and obesity and partner-based programs in oncology.

Key Statistics

Ownership: Public

Web Site: Arrowhead Research Corporation
Symbol: ARWR

Medical Device

Company News
Arrowhead Research Corporation (ARWR) To Present At Jefferies and Co. 2015 Healthcare Conference 5/27/2015 11:19:28 AM
Arrowhead Research Corporation (ARWR) Reports Fiscal 2015 Second Quarter Financial Results 5/12/2015 11:04:23 AM
Arrowhead Research Corporation (ARWR) Presents Data On Potential RNAi Candidate Targeting Factor 12 Mediated Angioedemic And Thromboembolic Diseases 5/7/2015 11:11:21 AM
Arrowhead Research Corporation (ARWR) Completes Dosing Healthy Volunteers And Initiates Transition To Patients In Phase 1 Study Of ARC-AAT 5/5/2015 10:40:10 AM
Arrowhead Research Corporation (ARWR) Publishes Data On Advances In Subcutaneous siRNA Delivery 4/30/2015 9:59:48 AM
Arrowhead Research Corporation (ARWR) To Present At Upcoming Conferences 4/29/2015 12:11:43 PM
Arrowhead Research Corporation (ARWR) Cleared To Proceed With Multiple Dose Phase 2b Study Of ARC-520 4/13/2015 11:06:30 AM
Novartis AG (NVS) Unloads RNAi Portfolio to Arrowhead Research Corporation (ARWR) for $35 Million 3/5/2015 6:08:11 AM
Arrowhead Research Corporation (ARWR) To Present At 2015 Barclays Global Healthcare Conference 3/4/2015 11:22:02 AM
Arrowhead Research Corporation (ARWR) Begins Phase 1 Trial Of ARC-AAT For Treatment Of Liver Disease Associated With Alpha-1 Antitrypsin Deficiency 2/23/2015 12:07:02 PM